initial public offerings (IPOs) trading on American exchanges

Friday, October 30, 2026

ContextLogic (OTCMKTS:LOGC)

ContextLogic (formerly the parent company of the e-commerce marketplace Wish) transformed from a struggling online retailer into a publicly traded business-ownership and acquisition platform. 


Key Milestones and Changes
  • Sale of Wish: In early 2024, ContextLogic sold its core Wish e-commerce operations for $173 million. 
  • Preservation of Tax Assets: Instead of liquidating, the company pivoted to preserve roughly $2.9 billion in net operating losses (NOLs) to shield future corporate profits from taxes. 
  • Delisting from Nasdaq: The company voluntarily delisted from Nasdaq in mid-2025 and moved to trade over-the-counter on the OTCQB market under the ticker symbol LOGC. 
  • Corporate Reorganization: In August 2025, ContextLogic completed a corporate restructuring, making ContextLogic Inc. a subsidiary of ContextLogic Holdings Inc. 
  • Acquisition of US Salt: In early 2026, ContextLogic completed a $907.5 million acquisition of US Salt in partnership with Abrams Capital and BC Partners Credit, shifting its primary business focus into the production and distribution of evaporated salt. 
  • Current Status: It trades on the OTC market as ContextLogic Holdings Inc.

Wednesday, October 28, 2026

OrthoPediatrics (KIDS) reported earnings on Tue 27 Oct 26 (a/h)

OrthoPediatrics Corp. is an orthopedic company, which engages in the design, development, and marketing of anatomically appropriate implants and devices for children with orthopedic conditions. It offers products relating to trauma and deformity, scoliosis, and sports medicine and other procedures. 
  • Sector: Healthcare
  • Industry: Medical Devices
  • Full Time Employees: 602
  • Founded by Erin Springer Yount and Nick A. Deeter in 2006 
  • Headquartered in Warsaw, Indiana
  • https://www.orthopediatrics.com
IPO Key Details
• IPO Date: October 12, 2017
• Offer Price: $13.00 per share

 
 
 



OrthoPediatrics posts record Q3 2026 revenue $72.7M (+19% YoY), raises 2026 revenue outlook to $270–$273M

  • Record Q3 revenue $72.7M, +19% YoY, driven by implants and OPSB growth.
  • GAAP EPS loss improved to -$0.25 versus -$0.50 last year.
  • Q3 2026 non-GAAP EPS was -$0.23, an improvement of 4% year over year.
  • Company missed Q3 2026 EPS estimates but exceeded revenue estimates.
  • Adjusted EBITDA reached record $6.9M, ~10% margin, reflecting strong operating leverage.
  • Gross margin steady at 74% despite mix shift toward lower-margin but accretive OPSB.
  • Free cash flow positive $1.6M versus -$3.4M prior year, guidance reiterated.
  • 2026 revenue outlook raised to $270–$273M from $265–$269M, 14–16% growth; EBITDA ~$25M maintained.
  • OPSB bracing grew above 20%, now over 60 clinics and 34 systems.
  • International revenue rose 18% to $14.8M, led by EMEA; LatAm constrained by set discipline.
  • Super Cycle products early but ramping, with major contributions expected in 2027 and beyond.
  • Main risks include clinic expansion costs, Brazil/LatAm set pullback, and lumpy 7D and set sales.
  • Main concern is sustainability of growth and margin expansion amid clinic investments and cautious LatAm deployment.

Sunday, October 18, 2026

Summit Midstream Corporation (SMC)

Summit Midstream Partners, LP priced its initial public offering (IPO) of 12.5 million common shares at $20.00 per share on September 27, 2012, and began trading on the New York Stock Exchange under the ticker symbol SMLP, later transitioning its corporate structure to Summit Midstream Corporation (NYSE: SMC). 
  • Sector: Energy
  • Industry: Oil & Gas Midstream
  • Headquarters: Houston, Texas
  • Full Time Employees: 296
  • Current Ticker/Structure: SMC (Summit Midstream Corporation) following its corporate conversion to a C-corporation
  • https://www.summitmidstream.com

 
 


Thursday, October 8, 2026

==Pacira BioSciences (PCRX) to be acquired by Viatris (VTRS) for $36.50/share cash

Viatris agreed to buy all outstanding Pacira shares for $36.50 each in cash, valuing Pacira's equity at about $1.65 bln.
  • Pacira adds marketed non-opioid pain products EXPAREL and ZILRETTA; the company generated about $746 mln of revenue and $177 mln of adjusted EBITDA in the last 12 months ended June 30, 2026.
  • Viatris said the deal should expand its U.S. innovative medicines capabilities, be synergistic with its fast-acting meloxicam opportunity, and be immediately accretive to financial guidance metrics.
  • The transaction is expected to close by the end of 2026 and Viatris said it preserves financial flexibility under its capital allocation strategy.




Friday, October 2, 2026

Okeanis Eco Tankers (ECO) : 3-year performance

Okeanis Eco Tankers Corp., a shipping company, owns and operates tanker vessels worldwide. It operates a fleet of 16 tanker vessels comprising eight modern Suezmax tankers and eight modern VLCC tankers focusing on the transportation of crude oil. 
Ticker:  ECO
USO IPO
December 11, 2023: First day of trading on the New York Stock Exchange (NYSE) under the ticker symbol ECO, with a secondary listing remaining on the Oslo Børs under the ticker code “OET”.

Prior listings:
  • First day of trading on Oslo's Merkur Market (now Euronext Growth) following a USD 100 million initial public offering.
  • March 8, 2019: Began trading on Euronext Expand (formerly Oslo Axess)
  • January 29, 2021: First day of trading on the main board of the Oslo Stock Exchange (Oslo Børs) under the symbol OET, following a transfer from Euronext Expand.